The drug "Nakom" describes the instruction as a combined anti-Parkinsonian drug. The use of this drug significantly increases dopaminergic transmission and significantly reduces the manifestation of painful symptoms due to the conversion of the active component to dopamine by decarboxylation in the brain. In this case, the therapeutic effect of the use of the drug "Nakom" (the instruction confirms this) manifests itself within the first twenty-four hours after administration. The greatest result is achieved seven days after the start of treatment. As for the half-life, it is from three to fifteen hours after using the antiparkinsonian drug Nakom. The analogs of this medicine - the capsules "Duelin", "Tremonorm" and "Cinema" - have a similar mechanism of action.
This drug is produced in the form of oval biconvex tablets of blue color. Each dragee contains two hundred and fifty milligrams of levodopa and twenty-seven milligrams of carbidopa monohydrate as active elements. Auxiliary ingredients are microcrystalline cellulose, pregelatinized starch, magnesium stearate, corn starch and blue indigotine.
Take Nakom pills, the instructions for use recommends for the treatment of people suffering from Parkinson's syndrome and Parkinson's disease. In addition, specialists quite often prescribe this drug to patients who use multivitamins containing pyridoxine hydrochloride.
To take the antiparkinsonian drug Nakom, the instruction strictly does not recommend people with individual intolerance to levodopa and carbidopa monohydrate, as well as an allergic reaction to any other auxiliary components. In addition, the list of contraindications includes angle-closure glaucoma, renal failure, melanoma, pregnancy, and liver failure. Also, do not take this drug and non-selective monoamine oxidase inhibitors at the same time. In addition, contraindications are up to eighteen years of age and the lactation period.
Among the most common adverse reactions triggered by the use of the drug "Nakom", experts distinguish a skin rash, leukopenia, angioedema, anemia, agranulocytosis and thrombocytopenia. In addition, there is a risk of developing malignant melanoma, arterial hypertension, stomach ulcers and hematuria. Anorexia, insomnia, confusion, bruxism, hallucinations, sleep disturbance, psychotic attacks, disorientation, lethargy, paranoid thinking, paresthesia, headache, dyskinesias, convulsions, ataxia and chorea can also occur as a result of taking Nakom tablets. The instruction also indicates the risk of shortness of breath, bitterness or dry mouth, delayed urination, loss of consciousness, increased sweating and darkening of sweat.